

6.107

Molecular Cancer Therapeutics
2013 IMPACT FACTORAACR
American Association
for Cancer Research

Molecular Cancer Therapeutics

[Home](#) | [OnlineFirst](#) | [Current Issue](#) | [Past Issues](#) | [Subscriptions](#) | [Alerts](#) | [Feedback](#) | [AACR Publications](#) | [CME](#) | [AACR Home](#)

User Name

Password

LOG-IN

Go

Advanced Search

The Combination of Cannabidiol and Δ^9 -Tetrahydrocannabinol Enhances the Anticancer Effects of Radiation in an Orthotopic Murine Glioma Model

Katherine A. Scott, Angus G. Dalgleish, and Wai M. Liu*

+ Author Affiliations

*Corresponding Author:

Wai Liu, Department of Oncology, Division of Clinical Sciences, St George's, University of London, Second Floor, Jenner Wing, London, SW17 0RE, United Kingdom. Phone: 44-20-8725-5037; Fax: 44-20-8725-0158; E-mail: w.liu@sgul.ac.uk

Abstract

High-grade glioma is one of the most aggressive cancers in adult humans and long-term survival rates are very low as standard treatments for glioma remain largely unsuccessful. Cannabinoids have been shown to specifically inhibit glioma growth as well as neutralize oncogenic processes such as angiogenesis. In an attempt to improve treatment outcome, we have investigated the effect of Δ^9 -tetrahydrocannabinol (THC) and cannabidiol (CBD) both alone and in combination with radiotherapy in a number of glioma cell lines (T98G, U87MG, and GL261). Cannabinoids were used in two forms, pure (P) and as a botanical drug substance (BDS). Results demonstrated a duration- and dose-dependent reduction in cell viability with each cannabinoid and suggested that THC-BDS was more efficacious than THC-P, whereas, conversely, CBD-P was more efficacious than CBD-BDS. Median effect analysis revealed all combinations to be hyperadditive [T98G 48-hour combination index (CI) at FU_{50} , 0.77–1.09]. Similarly, pretreating cells with THC-P and CBD-P together for 4 hours before irradiation increased their radiosensitivity when compared with pretreating with either of the cannabinoids individually. The increase in radiosensitivity was associated with an increase in markers of autophagy and apoptosis. These *in vitro* results were recapitulated in an orthotopic murine model for glioma, which showed dramatic reductions in tumor volumes when both cannabinoids were used with irradiation (day 21: $5.5 \pm 2.2 \text{ mm}^3$ vs. $48.7 \pm 24.9 \text{ mm}^3$ in the control group; $P < 0.01$). Taken together, our data highlight the possibility that these cannabinoids can prime glioma cells to respond better to ionizing radiation, and suggest a potential clinical benefit for glioma patients by using these two treatment modalities. *Mol Cancer Ther*; 1–13. ©2014 AACR.

Received May 12, 2014.

Revision received September 8, 2014.

Accepted September 23, 2014.

©2014 American Association for Cancer Research.

 CiteULike  Connotea  Delicious  Digg  Facebook  Google+

 Reddit  Twitter

What's this?

This Article

Published OnlineFirst November 14, 2014; doi: 10.1158/1535-7163.MCT-14-0402

» Abstract

» Full Text (PDF)

- Classifications

» Small Molecule Therapeutics

- Services

» Email this article to a colleague

» Alert me when this article is cited

» Alert me if a correction is posted

» Similar articles in this journal

» Similar articles in PubMed

» Download to citation manager

» Request Permissions

» patientACCESS

+ Google Scholar

+ PubMed


+ Social Bookmarking

:: AACR Publications Home ::

AACR American Association
for Cancer Research

Current Issue

November 2014, 13 (11)

Alert me to new issues of
Molecular Cancer Therapeutics

About the Journal

Instructions for
Authors/Editorial Policies

Submit a Manuscript

Author Services Center

Editorial Board

Information for Subscribers

Information for Reviewers

Information for Librarians

Information for Advertisers

Permissions & Reprints

E-mail Alerts & RSS Feeds
[Free]

Feedback

Cancer Discovery

Cancer Discovery News

Cancer Epidemiology
Biomarkers & Prevention

Cancer Immunology Research

Cancer Immunology Essentials

Cancer Prevention Research

[Cancer Research](#)

[Clinical Cancer Research](#)

[Molecular Cancer Research](#)

[AACR Publications CME](#)

[Cancer Prevention Journals Portal](#)

[Cancer Reviews Online](#)

[Annual Meeting Education Book](#)

[Meeting Abstracts Online](#)

[Help](#)

Most [Read](#) [Cited](#)

1. Highlights of This Issue
2. Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
3. Highlights of This Issue
4. The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation
5. Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma

[» View all Most Read articles](#)

[Home](#) [OnlineFirst](#) [Current Issue](#) [Past Issues](#) [Subscriptions](#) [Alerts](#) [Feedback](#) [AACR Publications](#) [CME](#) [AACR Home](#)

Copyright © 2014 American Association for Cancer Research

Online ISSN: 1538-8514

Print ISSN: 1535-7163